DUBLIN, November 3, 2017 /PRNewswire/ --
The "CAR T-cell Therapy for Multiple Myeloma - A Pipeline Analysis Report" report has been added to Research and Markets' offering.
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma: An insight
CAR T-cell Therapy for Multiple Myeloma - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
The CAR T-cell therapy for multiple myeloma pipeline analysis report includes ongoing clinical and non-clinical trends in the global CAR T-cell therapy for multiple myeloma.
Most of the pipeline therapeutics are in early stages of development; there is no CAR T-cell therapy approved to date for multiple myeloma treatment, but other treatments are available. A long-lasting and less-frequent dose can impact the overall multiple myeloma market.
In recent past, many pilot studies and early clinical trials have shown very promising results in the treatment of multiple myeloma with CAR T-cell therapy. However, the market has yet to witness the approval of the first CAR T-cell therapy for multiple myeloma, and it may take a few years from now. The currently available treatment for multiple myeloma include chemotherapy and other drugs, bisphosphonates, radiation, surgery, stem cell transplant, and plasmapheresis.
According to the National Cancer Institute (NIH), in 2017, there will be 30,280 new cases of myeloma and an estimated 12,590 deaths occur due to this disease in the US.
- Juno Therapeutics
- Kite Pharma
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Chimeric Antigen Receptor (Car) T-Cell Therapy For Multiple Myeloma: An Insight
Part 05: Major Regulatory Authorities
Part 06: Pipeline Landscape
Part 07: Comparative Analysis
Part 08: Indication Analysis
Part 09: Therapeutic Assessment By Therapy
Part 10: Therapeutic Assessment By Roa
Part 11: Therapeutic Assessment By Target
Part 12: Key Companies
Part 13: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/xcwd9c/car_tcell
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets